Introduction
Increased stemness and cancer cell plasticity have proved important mechanisms of anticancer drug resistance [1] . Synthetic lethality of specific groups of tumor cells is a promising approach mode to selective tumor cell targeting without the involvement of normal cell-induced death pathways. NOTCH signaling is linked to Olaparib (a PARP (Poly ADP Ribose Polymerase) inhibitor) resistance and commonly contributes to PARP inhibitor resistance; transcription factor dynamics effectively identify targets for intervention in chemotherapy-resistant cancers [2] . Combined sigma-2 receptor ligands and PARP inhibitors may synergistically trigger tumor cell death in certain breast cancer cells [3] . PARP inhibitors target poly (ADP-ribose) polymerase to potentiate synthetic lethality, particularly in patients with germ-line mutations in either BRCA1 or BRCA2 [4] .
In such context, the combinatorial presence of two-gene mutation, deletion or suppression, as by chemical compounds or small interfering RNAs, constitutes a vital mode of potential control of double-strand break repair in activating tumor cell death pathways. PARP inhibitors inhibit single-stranded DNA repair and induce synthetic lethality in cells with deficient homologous recombination, as in ovarian cancers showing mutation of BRCA1 or 2 [5] . Cell-cycle checkpoints and DNA repair pathways function to maintain genome stability and RAD54B constitutes an ideal target for synthetic lethality with targeting specific genes associated with carcinogenesis [6] . Resection-dependent canonical non-homologous end joining is significantly associated with deletions and translocations in checkpoint G1 phase, with consequent initiating events in tumorigenesis [7] . Activation of reactive oxygen species generation in particular is important in the inhibition of colon cancers [8] .
Synthetic Lethality
PARP inhibition acting within a BRCA-deficient context allows for the emergence of synthetic lethality and is particularly applicable in germline BRCA mutations.
Such germline deficiency of BRCA1 and BRCA2 genes and proteins allows for the potential application of such agents as hypoxia, combinatorial chemotherapeutics and the suppression of DNA helicases within the given contexts of defective homologous recombination pathways and also of upstream defects in the Fanconi Anemia pathway. Many efforts have shown the viability of both natural and artificial genetic code variations rather than the development of devastating global proteome modification [9] . Epigenetic regulatory gene mutations and synthetic lethality of cancer cells with loss-of-function mutations are being investigated in many clinical trials [10] . Some 50% of high-grade serous ovarian carcinomas have defective BRCA 1/2 genes involved in homologous recombination [11] . Open Access 2 hence a core phenomenon in carcinogenetic pathways in a manner that dictates steps in creating tumor formulated genetic pathways within the context of defective double-strand break repair. Double strand breaks are highly cytotoxic DNA lesions and their accurate repair by non-homologous end-joining or homologous recombination determines genomic integrity and is strongly affected by the local chromatin environment [23] .
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An error-free mechanism such as homologous recombination, in contrast to end-joining strand joining, allows for the prevention of created genetic mutations (double strand breaks) that in turn are required for carcinogenesis to be induced.
Hereditary Breast/Ovarian Tumors
The hereditary breast and ovarian tumors are linked in many patients to a defective homologous recombination series of pathways implicating many of their component mechanistic components either individually or in combination. BRCA1 and BRCA2 mutations are predominantly involved in such a phenomenon. PARP inhibitors induce significant tumor responses in cancer patients carrying germline BRCA1/2 mutations and may be useful also in the treatment of castration-resistant prostate cancer [24] . Aberrant expression of casein kinase 2 is implicated in prostate carcinogenesis and its suppression represses androgen-dependent prostate cancer cells by attenuating the androgen receptor signalling pathway [25] .
BRCA2 in particular, but also BRCA1, are implicated in other organ systems of carcinogenesis that include pancreas and prostate, and also lymphomas and leukemias and thymic tumors, as evidenced in animal transgenic models.
Such contexts of carcinogenesis appear linked to other functions and dysfunctions of BRCA genes and proteins in the processes of cell proliferation. Cyclin-dependent kinase mutations have been described in many tumors and have been suggested as a cause of defective DNA repair in ovarian cancer [26] .
Cell Proliferation
Proliferation-based creation of double-strand breaks is a significant mechanistic setting for the role of normal homologous recombination pathways in repairing double-strand breaks and in the prevention of carcinogenesis. This double strand DNA break repair by homologous recombination protects genomic stability and involves the formation of the RAD51 nucleofilament, which in turn facilitates the search for a homologous sequence and invasion of the template DNA strand [27] . Regulation of end-processing is critical for accurate DNA repair involving a switch between homologous recombination and non-homologous end joining [28] . Added to this is the under-estimated role of p53 mutations in the hereditary induction of tumorigenesis pathways by BRCA gene defects.
Synthetic viability involves a combination of altered genes that can rescue the lethal effects of a single gene alteration and may account for drug resistance of tumor cells; parameters may include copy number change, whole-exome mutation, expression profile [29] . Such a phenomenon may also account in part for the organ-site selectivity of tumors in hereditary breast and ovarian cancer patients that are BRCA mutant carriers.
Cancer Phenotypes
The basal-like breast cancers in BRCA1 mutant carriers and the luminal breast cancer BRCA2 mutant carriers are classic distinctions that evolve within the progression of homologous recombination dysfunction. It is significant to apply the potential roles of synthetic lethality and of synthetic viability pathways in terms also of dosage phenomena in these pathways and to understand individual molecular components involved in repair of double strand breaks. The construction of transcriptional regulatory
BRCA Mutants
Within-pathway and inter-pathway defects of BRCA and other genes such as other components in the homologous recombination pathways permit the utilization of two gene defects on the same chromosome, in particular, to operate in synchronous fashion and activate tumor cell apoptosis or other forms of cell death. Superoxide dismutase1 operates also as a nuclear transcription factor, as RNA binding protein, as a synthetic lethal interactor and as a signal modulator in glucose metabolism, in distinctly different context of its antioxidant enzyme action [12] .
It is further to such potential approaches that clinical trials with inhibitors of PARP (poly (ADP-ribose) polymerase), especially Olaparib, are utilized in the context of BRCA1 and BRCA2 deficits to induce selective targeting of proliferating and progressing carcinogenetic cells. Beta lactase stimulate apoptosis through the mitochondrial pathway and may induce anticancer effect in acute lymphocytic leukaemia cells [13] . Synthetic lethality develops between interacting poly(ADP-ribose) glycohydrolase and BRCA1, BRCA2, PALB2, FAM175A (ABRAXAS) and BARD1 [14] . A prospective targeting of PTEN-deficient tutors is based upon altered glutamine metabolism, DNA replication and DNA damage response [15] . In addition, the retinoblastoma tumor suppressor also binds to DNA double-strand breaks and this depends on E2F1 and ATM kinase and promotes repair via homologous recombination, thus leading to uncontrolled cell proliferation [16] .
It is within the spectral utilization of biomarkers such as RAD51 that interfering microRNAs appear to evolve as an induced potential for defective homologous recombination pathways. RAD51D-deficiency shifts double strand break repair toward highly deleterious single-strand annealing and end-joining processes with loss of significant chromosomal segments [17] .
Homologous Recombination
Homologous recombination is essentially an error-free repair mechanism that operates within the processes of meiosis; it allows for the repair of double-strand breaks inherent to the meiosis phases I and II that allow repair through sister chromatid pairing. Genetic crossover between homologous chromosomes is involved in meiosis-implicated processes in the creation of diversity in gene constitution. In phase II of meiosis the sister chromatids segregate individually within separate daughter gametes by utilizing the mechanisms involving created unique paternal and maternal genetic determinants in developing genetic diversity.
Hence, meiosis is integrally complexed as a system utilization of homologous recombination in the setting mechanics of genetic crossover that is inherently beneficial in inducing genetic diversity. Such contextual conditioning of meiosis is reflected in the essential functions and dysfunctions of impaired homologous recombination in the formulated emergence of carcinogenetic pathways. Thiazolidinones induce antimicrobial, anti-inflammatory, anti-oxidant and anticancer effects as in glioblastoma [18] .
The levels of several enzymes involved in removal of exocyclic adducts from DNA are altered during carcinogenesis [19] . No targeted agents are effective in KRAS-mutant cancer due to activated compensatory pathways resulting from augmented homologous recombination repair signaling; there is increased recruitment of RAD51 to radiation-indued DNA double-strand breaks [20] . Depletion of USP39, a deubiquitinase, causes significantly reduced efficiency in pre-mRNA, and is a critical gene for viability of KRAS-dependent cancer cells [21] .
Genetic Diversity
Essential genes are required for viability of the organisms [22] . Mechanistic pathways in inducing genetic diversity during meiosis are Open Access 3 networks may help understand underlying regulatory mechanisms in carcinogenesis [30] . Double strand breaks are significant in inducing stalled replication forks involving, in particular, the G1-S checkpoint in the case of mutated BRCA1 and of the G2-M checkpoint in mutated BRCA2 patients.
Sci Forschen
Lesion tolerance pathways allow cells to bypass replication-blocking lesions in their genome with the creation of daughter strand gaps opposite replication-blocking lesions; most gaps are then repaired by Homology Directed Gap Repair utilising RecA [31] .
Hence, specific dynamics of activation of cell-cycle checkpoints, such as the progression of cell cycling by p21, are essential contextual parameters in the dysfunctional or failed repair by aberrant homologous recombination pathways. High grade serous ovarian carcinoma is molecularly heterogeneous but 50% of them show genetic features of homologous recombination deficiency [32] .
BRCA Mutant Carriers
Nuclear localization domains and the DNA binding domain of BRCA1 and BRCA2 proteins underlie dynamics of progression in mutated BRCA carriers and allow for the C-terminal domain in particular to affect also oligomer fold domains to involve aberrant functionality of the homologous recombination processes. The E3 ubiquitin ligase domain of BRCA1 is not implicated in degradation pathways but allows for the interactions of the BRCA1-BALD1 heterodimer complex domain and implicates BALD1 as a significant high-penetrance gene in breast carcinogenesis.
DNA Synthesis and Cell Cycling
Both DNA synthesis, as seen in the subtype homologous recombination mechanism of synthesis-linked end-annealing, and cell proliferation pathways are central characteristics of potential breast carcinogenesis as dictated particularly by the BRCA1 and BRCA2 aberrant pathways. The roles particularly of BRCA1 in gene transcription and cell cycle progression are therefore significant in carcinogenesis within a setting of further aberrant roles of a dysfunctional homologous recombination series of mechanisms.
Homologous recombination may actually occur not only in S/G2 cells where intact sister chromatids are available as donor templates but may implicate also double strand break repair within actively transcribed regions [33] .
It would appear that synthetic lethality is significant not only from a therapeutic point of view but also in the creation of aberrant pathways leading to aberrant homologous recombination repair pathways. Within such context, the application of PARP inhibitors and for anti-cancer agents such as radiation and platinum may sensitize cells to undergo cell death pathways, within the further conditioning settings of hypoxia and defects in BRCA1 and BRCA2 mutant carriers.
d,l-Sulforaphane may induce apoptosis in glioblastoma cells via reactive oxygen species-dependent in activation of STAT-3 phosphorylation in a dose-and time-dependent manner [34] . Families of tumor suppressor genes implicated in homologous recombination or mismatch repair may be related to genomic repair and promote carcinogenesis when defective; the hypoxia pathway may be associated with aggressive tumorigenesis and involve tumor-suppressor genes [35] .
Concluding Remarks
The coordinating roles of component proteins involved in homologous recombination are core physiologic mechanisms in dealing with doublestrand breaks that accompany the genesis not only of tumorigenesis, but also processes that accompany physiologically the genetic crossover in meiosis and thus allow for genetic diversity. During epithelialmesenchymal transition-mesenchymal epithelial transition, DNA repair involving non-homologous end joining and homologous recombination is critical in reactivation of dormant tumor cells [36] .
The implications of mechanistic DNA synthesis and of cell cycle progression come to play essential roles in determining the effective or aberrant homologous recombination repair processes in safeguarding the genome from error-induced mutagenesis and subsequent potential carcinogenesis.
Breast cancer associated (BRCA) genes are critically implicated in DNA repair, and their germline mutations are common in ovarian carcinoma [37] . Many common variants of DNA repair genes may induce small effect sizes that do not impact stringent significance testing criteria [38] .
DNA Repair proteins may be involved in more than one repair pathways; opening the possibility of combined targeting of different repair mechanisms like for example non-homologous end joining and base excision repair [39] . Synthetic viability outcomes in synthesis pathways are probably an underestimated system of pathways that may potentially contribute to aggressive cancer phenotypes and may model parameters inherent to dynamic DNA synthesis and cell cycling.
